Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Virax Biolabs Group Ltd. (VRAX:NASDAQ), powered by AI.
Virax Biolabs Group Ltd. is currently trading at $0.15. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Virax Biolabs Group Ltd. on Alpha Lenz.
Virax Biolabs Group Ltd.'s P/E ratio is -0.1.
“Virax Biolabs Group Ltd. trades at a P/E of -0.1 (undervalued) with modest ROE of -109.6%.”
Ask for details →Virax Biolabs Group Ltd. is a company specializing in the development and distribution of diagnostic testing kits and related products for the detection and management of viral diseases. The primary purpose of Virax Biolabs is to provide healthcare solutions that aid in the early detection of viral pathogens, a crucial step in preventing the spread of infectious diseases and enabling effective medical intervention. Its products are vital across various sectors including healthcare institutions, government health departments, and research organizations. The company's innovations are particularly significant amid global health crises, offering crucial tools for public health surveillance and response. By serving a diverse market, Virax Biolabs plays a key role in supporting public health initiatives and enhancing the capacity of healthcare systems to manage viral threats effectively. The company's operations underscore the importance of advancing medical diagnostics to safeguard community health and well-being.
“Virax Biolabs Group Ltd. trades at a P/E of -0.1 (undervalued) with modest ROE of -109.6%.”
Ask for details →Virax Biolabs Group Ltd. (ticker: VRAX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 19 employees. Market cap is $552,091.
The current price is $0.148 with a P/E ratio of -0.09x and P/B of 0.1x.
ROE is -109.58% and operating margin is -97344.76%. Annual revenue is $6,331.